Outcomes of Mini-Gastric Bypass with Various Biliopancreatic Limb Lengths

Bariatric surgery is the most effective therapy for obesity, leading to a sustained weight loss, remission of co-morbidities, and a decreased mortality. In 1997 Rutledge introduced the mini-gastric bypass (MGB). This entails a gastrojejunal anastomosis between a long gastric pouch and a jejunal omega loop. Previous studies demonstrated the MGB to be a safe procedure with low mortality and morbidity. The limiting step to broaden the utilization of MGB, is the lack of standardization. Currently, there is no standard guideline for the optimal biliopancreatic (BP) limb length. Technical variations limit the comparability of the currently literature and therefore hinder the obtaining of a consensus on the best way to determine the BP-limb length.
This is a single center retrospective cohort study. From January 2015 to December 2016, all patients who underwent a mini-gastric bypass at the Center Obesity North-Netherlands were included in a prospective database and will be retrospectively analyzed. The follow-up information will be included up to 5 years after the initial surgery. The aim of this study is to describe the MGB procedure as performed in our center and to assess both efficacy and safety of this technique. Furthermore, the aim is to investigate the impact of various BP-limb lengths in terms of weight loss and resolution of co-morbidities.

The purpose of the study is to evaluate the outcomes and midterm follow-up in the mini-gastric bypass in terms of weight loss, resolution of co-morbidities and the impact of different BP-limb lengths.

Day of the surgery and follow-up visit 1 (10-14 months), 2 (18-30 months), 3 (30-42 months), 4 (42-54 months) and 5 (54-66 months) years after surgery.

None